Submission 193
Moderna Australia
Submitter group: Companies.
An AI model identified the submitter group and wrote the summary, key points and recommendation summaries. Counts do not measure importance or merit.
Summary
Read the original submission for the full text.
Moderna Australia argues AI-enabled life sciences should be a national priority, with trusted biomedical data infrastructure, multidisciplinary skills, sovereign capability built through global connection, and risk-based, internationally aligned regulation that applies existing frameworks first. It cautions that AI's drug-discovery potential should not be overstated and links AI to translation, manufacturing and health security.
Key points
Quotes are the submitter’s own words. Text taken from documents, including scanned pages read by text-recognition software, can differ from the PDF. Check the original. Listed in the same order as on the submission’s page in the interactive guide.
Argues that AI could raise scientific productivity, but policy should target demonstrated outcomes rather than adoption for its own sake.
AI has the potential to increase scientific productivity and accelerate biomedical innovation, but policy should focus on demonstrated scientific, health and economic outcomes rather than AI adoption for its own sake.
Argues that sovereign AI investment should focus on areas of comparative advantage such as life sciences.
Australia should focus sovereign AI investment on areas of comparative advantage. Health and medical research, biotechnology and advanced manufacturing provide a significant opportunity.
Argues that health data should be treated as strategic research infrastructure with trusted access, without unrestricted access.
These resources should increasingly be regarded as strategic research infrastructure. The objective should not be unrestricted access to health data. Ongoing public trust, privacy, consent, security and appropriate governance are essential. Rather, Australia should develop trusted mechanisms that allow appropriately authorised academic and industry researchers to use high-quality health and research data while protecting individuals.
Argues that data sovereignty should not become isolation that deters international research collaboration.
Importantly, data sovereignty should not inadvertently become data isolation. Requirements that unnecessarily prevent secure international research collaboration could reduce Australia's attractiveness as a location for global R&D and limit the ability of Australian researchers to contribute to international science.
Argues that workforce needs extend beyond AI specialists to people who work across disciplines.
The emerging workforce challenge is not simply a shortage of AI specialists. Life sciences increasingly require people who can operate across disciplines: scientists who understand computational methods, data scientists who understand biology, clinicians who can work with advanced analytics, and regulators who understand how AI generated evidence should be evaluated.
Argues that the AI Safety Institute could support regulators by providing technical insight on emerging capabilities and risks.
Australia's AI Safety Institute can complement this capability by providing technical insights on emerging AI capabilities and risks to support regulators and agencies
Recommendations
Recommendations are shown beside the submission’s own words. Listed in the same order as on its page in the interactive guide.
Prioritise AI-enabled life sciences within existing AI, health and research frameworks: target existing strengths and measurable health/economic value, strengthening collaboration among industry, universities, medical research institutes, healthcare organisations, government and regulators.
Make AI-enabled life sciences a priority within existing national AI, health and research frameworks, focusing government support on areas where Australia has existing scientific and industrial strengths and where AI can deliver measurable health and economic value. This should include stronger collaboration between industry, universities, medical research institutes, healthcare organisations, government and regulators.
Build AI-ready health, clinical, genomic and research data infrastructure for authorised academic and industry researchers, with standards, interoperability, privacy and governance safeguards supporting secure international research collaboration.
Build trusted AI ready biomedical data infrastructure, enabling responsible use of Australian health, clinical, genomic and research data by appropriately authorised researchers across academia and industry through appropriate standards, interoperability, privacy and governance, while supporting secure international research collaboration.
Develop sovereign capability through multidisciplinary AI/life-sciences skills, careers and partnerships; support responsible institutional adoption and consistent AI governance while attracting international R&D, investment and collaboration.
Develop sovereign capability through people, institutions and strategic partnerships, investing in multidisciplinary AI and life sciences skills and career pathways, supporting universities and medical research institutes to adopt AI responsibly, and developing greater consistency in institutional AI governance while attracting international R&D, investment and collaboration into Australia.
Enable adaptive, risk-based regulation: equip TGA/relevant agencies to apply existing frameworks by context/risk; add AI-specific requirements only for genuine gaps, aligning where possible with leading international regulators and evolving international AI governance.
Enable AI innovation through risk-based, internationally aligned and adaptive regulation, ensuring the TGA and other relevant agencies have the capability to apply existing regulatory frameworks to AI according to context and risk, with new AI-specific requirements introduced only where genuine gaps exist and aligned, where possible, with leading international regulators and evolving international AI governance approaches.
Connect AI research with translation, advanced manufacturing and resilience: support validation, clinical development and commercialisation of Australian discoveries, attract private investment, and strengthen health security and pandemic preparedness.
Connect AI enabled research with translation, advanced manufacturing and national resilience, ensuring AI investment helps Australian discoveries progress through validation, clinical development and commercialisation, attracts private investment, and strengthens health security and pandemic preparedness.
Address sector-specific adoption barriers, especially for smaller biotech and medical technology companies: biomedical data, computational and biological expertise, compute, experimental validation and regulatory requirements.
High-quality biomedical data, specialised computational and biological expertise, computing infrastructure, experimental validation and regulatory requirements can all affect whether an AI enabled approach can progress from proof of concept into development. Policies intended to accelerate adoption should recognise these sector specific barriers, particularly for smaller companies that may not have access to the infrastructure and multidisciplinary capabilities available within larger organisations.
Bring biological scientists, clinicians, data scientists, engineers, computational scientists and industry together rather than treating AI research and life sciences separately.
Australia should similarly prioritise AI enabled science in areas where it possesses genuine comparative advantage. Biomedical research, biotechnology, clinical research and health are strong candidates. This should bring together biological scientists, clinicians, data scientists, engineers, computational scientists and industry rather than treating AI research and life sciences research as separate disciplines.
Encourage international companies' AI R&D with Australian institutions, support researchers' global participation, enable secure global AI access and strengthen university/institute-to-industry research pathways.
Policy should encourage international companies to undertake AI enabled R&D with Australian institutions, support Australian researchers to participate in global research programs, enable secure access to global AI platforms and capabilities, and create stronger pathways through which research can progress from universities and medical research institutes into industry.
Enable legitimate public-interest health research by public institutions and industry alike, subject to safeguards and governance; protect public trust, privacy, consent and security.
The objective should not be unrestricted access to health data. Ongoing public trust, privacy, consent, security and appropriate governance are essential. Rather, Australia should develop trusted mechanisms that allow appropriately authorised academic and industry researchers to use high-quality health and research data while protecting individuals. Access frameworks should enable legitimate research in the public interest regardless of whether it is undertaken by public research institutions or industry, subject to appropriate safeguards and governance.
Consider national infrastructure making appropriately governed biomedical datasets more discoverable, interoperable and usable across academia, medical research and industry.
Australia should therefore consider national infrastructure that makes appropriately governed biomedical datasets more discoverable, interoperable and usable for research across academia, medical research and industry.
Maintain international research connections while ensuring trusted Australian data use with appropriate Australian governance and benefit.
The objective should be trusted use of Australian data, with appropriate Australian governance and benefit, while maintaining the international connections upon which biomedical research depends.
Build multidisciplinary AI/biology capability through undergraduate education, PhDs, fellowships, industry placements and continuing professional development.
Australia should build this multidisciplinary capability deliberately through undergraduate education, PhD programs, fellowships, industry placements and continuing professional development.
Encourage joint industry-academic training in computational biology, bioinformatics, quantitative pharmacology, biostatistics, genomics, AI-enabled drug development and advanced biomanufacturing.
Australia should encourage joint industry and academic training programs in areas such as computational biology, bioinformatics, quantitative pharmacology, biostatistics, genomics, AI enabled drug development and advanced biomanufacturing.
Consider common principles and practical guidance for institutional AI research governance, reducing duplication while maintaining safeguards.
Australia should consider whether greater consistency in institutional AI governance, including common principles and practical guidance for AI use in research, could reduce duplication while maintaining appropriate safeguards.
Integrate AI governance into established research integrity, ethics and governance systems, with additional requirements proportionate to application risks.
AI governance should increasingly be integrated into these established research integrity, ethics and governance systems, with additional requirements proportionate to the risks associated with particular applications.
Maintain technically capable institutions, ongoing evaluation of emerging capabilities and risks, and adaptive regulatory settings without unnecessarily constraining lower-risk beneficial uses.
Australia’s regulatory and governance systems need to be able to identify and respond to material changes in AI capability as they emerge, without unnecessarily constraining lower risk and beneficial applications. This requires technically capable institutions, ongoing evaluation of emerging capabilities and risks, and regulatory settings that can adapt as evidence and international approaches develop.
Avoid treating literature-search tools like models generating regulatory evidence, or adding requirements when existing regulation adequately addresses risks.
An AI system assisting a scientist to search literature does not present the same risks as an AI model used to generate evidence supporting a regulatory decision about the safety or effectiveness of a medicine. Australia should avoid regulating these applications as though they are equivalent or imposing additional requirements where relevant risks are appropriately addressed through existing regulation.
Pursue regulatory interoperability wherever possible, including close engagement between the TGA and international counterparts.
Australia should therefore pursue regulatory interoperability wherever possible, including close engagement between the Therapeutic Goods Administration (TGA) and international counterparts.
Invest in regulatory science as part of Australian AI capability; ensure regulators have expertise and resources to evaluate sophisticated computational approaches.
At the same time, regulators need the expertise and resources to evaluate increasingly sophisticated computational approaches. Investment in regulatory science should therefore be considered part of Australia's AI capability, rather than simply a regulatory cost.
Consider AI, biotechnology and advanced manufacturing capabilities as interconnected components of national resilience.
Australia should consider AI capability, biotechnology capability and advanced manufacturing capability as increasingly interconnected elements of national resilience.
Maintain scientific and technical expertise within government agencies responsible for medicines regulation, health security, biosecurity and pandemic preparedness.
As AI enabled technologies evolve, agencies responsible for medicines regulation, health security, biosecurity and pandemic preparedness will require sufficient scientific and technical capability to evaluate emerging technologies and risks. Maintaining this expertise within government should be considered part of Australia's national AI capability.